Terran Biosciences

New York, United StatesFounded 201711–50 employeesterranbiosciences.comLinkedIn

Neuroimaging

Terran Biosciences is a biotech platform company developing therapeutics and technologies for neurological and psychiatric diseases. Its portfolio spans late-stage drug candidates, psychedelic drug design, and AI-enabled imaging software, including FDA-cleared NM-101 for neuromelanin MRI analysis.

Visit terranbiosciences.com ↗

Founded: 2017
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Terran Biosciences’ visible milestones point to continued development of its neuroscience portfolio and intellectual property rather than a disclosed new financing or commercial launch. The company acquired Concert’s CNS therapeutics on Mar 11, 2022, adding assets to its neurological and psychiatric drug-development efforts. Patent-related activity includes a filing titled “Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (imdai)” dated Sep 4, 2025, followed by patent activity on Jan 12, 2026 for serotonin receptor agonists and on Jan 16, 2026 for azepino-indoles for neurological and psychiatric disorders. Its listed pipeline spans TerXT, Idazoxan XR, eplivanserin and volinanserin, psychedelic and empathogen programs, and the Drug Design Engine. The company also lists NM-101, software for analyzing neuromelanin MRI scans. No company-specific partnership announcements, award announcements, product-launch announcements, or leadership changes are included here.

Market position

Terran Biosciences operates across several intersecting areas of neuroscience: drug development for psychiatric and neurological conditions, medicinal chemistry and prodrug design, psychedelic and empathogen research, and medical imaging software. Its listed programs include TerXT for schizophrenia, Idazoxan XR for schizophrenia and Alzheimer’s disease, serotonin 2A receptor candidates, and NM-101 for neuromelanin MRI analysis. The company describes NM-101 as FDA-cleared, while its therapeutic programs span different mechanisms and development approaches. The available company comparison list contains no distinct peer organizations, so naming specific competitors or making a direct relative ranking would be unsupported. Its differentiation is therefore best understood through the combination of pipeline assets, compound-design capabilities, and imaging software, not through a claimed market lead.

Growth & opportunities

Founded in 2017, Terran Biosciences has built a portfolio that combines therapeutic development, drug-design capabilities, and medical software. Its disclosed financing history includes a Seed round dated Jan 1, 2020 and a Venture Round dated Jan 1, 2022; neither round has an available amount, and no total funding figure can be established. The acquisition of Concert’s CNS therapeutics on Mar 11, 2022 marks a concrete portfolio-expansion milestone. The company’s listed products and programs now range from TerXT and Idazoxan XR to psychedelic and empathogen candidates, the Drug Design Engine, and NM-101. Patent activity recorded in September 2025 and January 2026 indicates continued work on compounds relevant to neurological and psychiatric disorders. The company is categorized in the 11–50 employee range, but the available figures do not provide a time series to measure hiring or workforce growth. Overall, the profile suggests a multi-program development strategy, while the absence of disclosed capital, clinical progress data, and launch milestones makes it difficult to determine the pace of advancement or identify a clear commercial inflection point.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Terran Biosciences distinct

reccy insights

What makes Terran Biosciences distinct

01Combines a neuroscience therapy pipeline with drug-design capabilities and AI-enabled medical software.
02Develops prodrugs and formulations intended to improve dosing and pharmacokinetic profiles.
03NM-101 is described as FDA-cleared software for analyzing neuromelanin MRI scans and supporting imaging workflows.
04Its psychedelic and empathogen programs include novel prodrugs and non-hallucinogenic derivatives.

Technology & products6

Technology & products

TerXT
A combination of xanomeline and trospium prodrugs designed for once-daily oral dosing and long-acting injections to treat schizophrenia.
Idazoxan XR
An extended-release alpha 2 adrenergic receptor antagonist for schizophrenia and Alzheimer’s disease, dosed once daily.
Eplivanserin and Volinanserin
Phase 3 selective serotonin 2A receptor antagonists for neuropsychiatric illnesses, developed alone or combined with psychedelics.
Psychedelic Therapeutics and Empathogens
A portfolio of psychedelic and empathogen compounds, including novel prodrugs and non-hallucinogenic derivatives, for neurological and psychiatric treatment.
Drug Design Engine
A medicinal chemistry platform creating novel compounds and prodrugs with improved pharmacokinetics and receptor binding profiles for neuroscience applications.
NM-101 AI Software Platform
A cloud-based, FDA-cleared software for analyzing neuromelanin MRI scans to assist diagnosis of neurological and psychiatric disorders.

Show all 6 products

+ 3 more: Psychedelic Therapeutics and Empathogens, Drug Design Engine, NM-101 AI Software Platform

Similar companies

Show all 6 companies

About Terran Biosciences

Products: TerXT, Idazoxan XR, Eplivanserin and Volinanserin, Psychedelic Therapeutics and Empathogens, Drug Design Engine, NM-101 AI Software Platform
Leadership: Sam Clark, Founder and CEOAnnette Madrid, Head of Clinical Research
Focus areas: Biotechnology, neuroscience, psychiatry, drug development, psychedelics, medical software, MRI, clinical research
Headquarters: New York, United States
Founded: 2017
Employees: 11–50
Patents granted: 55 (Crunchbase)